
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Cool Laser Optics (CLO) Inc., owner of patents regarding skin cooling, has reached an agreement with Lumenis Inc., a laser manufacturer, over issues regarding alleged infringement of certain CLO patents.